nodes	percent_of_prediction	percent_of_DWPC	metapath
Triamcinolone—CYP3A4—Cytarabine—lymphatic system cancer	0.0307	0.318	CbGbCtD
Triamcinolone—CYP3A4—Teniposide—lymphatic system cancer	0.0303	0.313	CbGbCtD
Triamcinolone—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0212	0.219	CbGbCtD
Triamcinolone—CYP3A4—Vincristine—lymphatic system cancer	0.0146	0.151	CbGbCtD
Triamcinolone—Haemorrhage—Teniposide—lymphatic system cancer	0.00405	0.00448	CcSEcCtD
Triamcinolone—Acute coronary syndrome—Fludarabine—lymphatic system cancer	0.00391	0.00432	CcSEcCtD
Triamcinolone—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.0039	0.00432	CcSEcCtD
Triamcinolone—Myocardial infarction—Fludarabine—lymphatic system cancer	0.00388	0.0043	CcSEcCtD
Triamcinolone—Neuropathy peripheral—Fludarabine—lymphatic system cancer	0.00388	0.0043	CcSEcCtD
Triamcinolone—Infection—Mechlorethamine—lymphatic system cancer	0.00387	0.00429	CcSEcCtD
Triamcinolone—Ecchymosis—Mitoxantrone—lymphatic system cancer	0.00381	0.00422	CcSEcCtD
Triamcinolone—Thrombophlebitis—Carmustine—lymphatic system cancer	0.0038	0.00421	CcSEcCtD
Triamcinolone—Diabetes mellitus—Carmustine—lymphatic system cancer	0.00378	0.00419	CcSEcCtD
Triamcinolone—Osteoporosis—Methotrexate—lymphatic system cancer	0.00375	0.00415	CcSEcCtD
Triamcinolone—Epistaxis—Fludarabine—lymphatic system cancer	0.00374	0.00414	CcSEcCtD
Triamcinolone—Arrhythmia—Teniposide—lymphatic system cancer	0.00362	0.004	CcSEcCtD
Triamcinolone—Injury—Carmustine—lymphatic system cancer	0.00358	0.00396	CcSEcCtD
Triamcinolone—Haemoglobin—Fludarabine—lymphatic system cancer	0.00357	0.00396	CcSEcCtD
Triamcinolone—Haemorrhage—Fludarabine—lymphatic system cancer	0.00356	0.00394	CcSEcCtD
Triamcinolone—Pharyngitis—Fludarabine—lymphatic system cancer	0.00353	0.00391	CcSEcCtD
Triamcinolone—Skin hyperpigmentation—Methotrexate—lymphatic system cancer	0.00353	0.00391	CcSEcCtD
Triamcinolone—Cardiac failure congestive—Mitoxantrone—lymphatic system cancer	0.00337	0.00373	CcSEcCtD
Triamcinolone—Folliculitis—Methotrexate—lymphatic system cancer	0.00334	0.0037	CcSEcCtD
Triamcinolone—Embolism—Methotrexate—lymphatic system cancer	0.00327	0.00362	CcSEcCtD
Triamcinolone—Arrhythmia—Fludarabine—lymphatic system cancer	0.00318	0.00352	CcSEcCtD
Triamcinolone—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.00316	0.0035	CcSEcCtD
Triamcinolone—Hypertension—Teniposide—lymphatic system cancer	0.00304	0.00337	CcSEcCtD
Triamcinolone—Cardiac arrest—Vincristine—lymphatic system cancer	0.00299	0.00331	CcSEcCtD
Triamcinolone—Muscular weakness—Carmustine—lymphatic system cancer	0.0029	0.00321	CcSEcCtD
Triamcinolone—Oedema—Teniposide—lymphatic system cancer	0.00288	0.00318	CcSEcCtD
Triamcinolone—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00287	0.00318	CcSEcCtD
Triamcinolone—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00287	0.00318	CcSEcCtD
Triamcinolone—Acute coronary syndrome—Bleomycin—lymphatic system cancer	0.00286	0.00317	CcSEcCtD
Triamcinolone—Infection—Teniposide—lymphatic system cancer	0.00286	0.00316	CcSEcCtD
Triamcinolone—Myocardial infarction—Bleomycin—lymphatic system cancer	0.00285	0.00315	CcSEcCtD
Triamcinolone—Tachycardia—Teniposide—lymphatic system cancer	0.00281	0.00311	CcSEcCtD
Triamcinolone—Malaise—Fludarabine—lymphatic system cancer	0.00279	0.00309	CcSEcCtD
Triamcinolone—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00278	0.00308	CcSEcCtD
Triamcinolone—Muscular weakness—Vincristine—lymphatic system cancer	0.00277	0.00307	CcSEcCtD
Triamcinolone—Pruritus—Mechlorethamine—lymphatic system cancer	0.00276	0.00305	CcSEcCtD
Triamcinolone—Cough—Fludarabine—lymphatic system cancer	0.0027	0.00299	CcSEcCtD
Triamcinolone—Convulsion—Fludarabine—lymphatic system cancer	0.00268	0.00297	CcSEcCtD
Triamcinolone—Abscess—Methotrexate—lymphatic system cancer	0.00265	0.00294	CcSEcCtD
Triamcinolone—Myalgia—Fludarabine—lymphatic system cancer	0.00264	0.00292	CcSEcCtD
Triamcinolone—Haemoglobin—Bleomycin—lymphatic system cancer	0.00262	0.0029	CcSEcCtD
Triamcinolone—Haemorrhage—Bleomycin—lymphatic system cancer	0.00261	0.00289	CcSEcCtD
Triamcinolone—Discomfort—Fludarabine—lymphatic system cancer	0.0026	0.00288	CcSEcCtD
Triamcinolone—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00258	0.00285	CcSEcCtD
Triamcinolone—Dyspnoea—Teniposide—lymphatic system cancer	0.00256	0.00284	CcSEcCtD
Triamcinolone—Petechiae—Methotrexate—lymphatic system cancer	0.00255	0.00283	CcSEcCtD
Triamcinolone—Oedema—Fludarabine—lymphatic system cancer	0.00253	0.0028	CcSEcCtD
Triamcinolone—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00253	0.0028	CcSEcCtD
Triamcinolone—Infection—Fludarabine—lymphatic system cancer	0.00251	0.00278	CcSEcCtD
Triamcinolone—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00249	0.00275	CcSEcCtD
Triamcinolone—Vomiting—Mechlorethamine—lymphatic system cancer	0.00248	0.00275	CcSEcCtD
Triamcinolone—Rash—Mechlorethamine—lymphatic system cancer	0.00246	0.00272	CcSEcCtD
Triamcinolone—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00246	0.00272	CcSEcCtD
Triamcinolone—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00246	0.00272	CcSEcCtD
Triamcinolone—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00244	0.0027	CcSEcCtD
Triamcinolone—Weight increased—Mitoxantrone—lymphatic system cancer	0.00241	0.00266	CcSEcCtD
Triamcinolone—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00239	0.00264	CcSEcCtD
Triamcinolone—Myocardial infarction—Vincristine—lymphatic system cancer	0.00237	0.00263	CcSEcCtD
Triamcinolone—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00237	0.00263	CcSEcCtD
Triamcinolone—Feeling abnormal—Teniposide—lymphatic system cancer	0.00237	0.00262	CcSEcCtD
Triamcinolone—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.00232	0.00257	CcSEcCtD
Triamcinolone—Nausea—Mechlorethamine—lymphatic system cancer	0.00232	0.00256	CcSEcCtD
Triamcinolone—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00231	0.00256	CcSEcCtD
Triamcinolone—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.0023	0.00255	CcSEcCtD
Triamcinolone—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00229	0.00254	CcSEcCtD
Triamcinolone—Haemoglobin—Carmustine—lymphatic system cancer	0.00229	0.00253	CcSEcCtD
Triamcinolone—Urticaria—Teniposide—lymphatic system cancer	0.00228	0.00253	CcSEcCtD
Triamcinolone—Haemorrhage—Carmustine—lymphatic system cancer	0.00228	0.00252	CcSEcCtD
Triamcinolone—Body temperature increased—Teniposide—lymphatic system cancer	0.00227	0.00252	CcSEcCtD
Triamcinolone—Erythema—Bleomycin—lymphatic system cancer	0.00227	0.00251	CcSEcCtD
Triamcinolone—Paraesthesia—Fludarabine—lymphatic system cancer	0.00227	0.00251	CcSEcCtD
Triamcinolone—Dyspnoea—Fludarabine—lymphatic system cancer	0.00225	0.00249	CcSEcCtD
Triamcinolone—Dyspepsia—Fludarabine—lymphatic system cancer	0.00222	0.00246	CcSEcCtD
Triamcinolone—Ulcer—Methotrexate—lymphatic system cancer	0.00222	0.00246	CcSEcCtD
Triamcinolone—Fatigue—Fludarabine—lymphatic system cancer	0.00218	0.00241	CcSEcCtD
Triamcinolone—Pain—Fludarabine—lymphatic system cancer	0.00216	0.00239	CcSEcCtD
Triamcinolone—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00215	0.00239	CcSEcCtD
Triamcinolone—Vasculitis—Methotrexate—lymphatic system cancer	0.00215	0.00238	CcSEcCtD
Triamcinolone—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00213	0.00235	CcSEcCtD
Triamcinolone—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00212	0.00235	CcSEcCtD
Triamcinolone—Hypersensitivity—Teniposide—lymphatic system cancer	0.00212	0.00235	CcSEcCtD
Triamcinolone—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.00212	0.00234	CcSEcCtD
Triamcinolone—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00211	0.00233	CcSEcCtD
Triamcinolone—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.0021	0.00233	CcSEcCtD
Triamcinolone—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00208	0.00231	CcSEcCtD
Triamcinolone—Asthenia—Teniposide—lymphatic system cancer	0.00206	0.00228	CcSEcCtD
Triamcinolone—Malaise—Bleomycin—lymphatic system cancer	0.00205	0.00227	CcSEcCtD
Triamcinolone—Pruritus—Teniposide—lymphatic system cancer	0.00203	0.00225	CcSEcCtD
Triamcinolone—Arrhythmia—Carmustine—lymphatic system cancer	0.00203	0.00225	CcSEcCtD
Triamcinolone—Skin exfoliation—Methotrexate—lymphatic system cancer	0.002	0.00222	CcSEcCtD
Triamcinolone—Body temperature increased—Fludarabine—lymphatic system cancer	0.002	0.00221	CcSEcCtD
Triamcinolone—Erythema—Carmustine—lymphatic system cancer	0.00198	0.00219	CcSEcCtD
Triamcinolone—Cough—Bleomycin—lymphatic system cancer	0.00198	0.00219	CcSEcCtD
Triamcinolone—Myalgia—Bleomycin—lymphatic system cancer	0.00193	0.00214	CcSEcCtD
Triamcinolone—Back pain—Carmustine—lymphatic system cancer	0.00192	0.00212	CcSEcCtD
Triamcinolone—Discomfort—Bleomycin—lymphatic system cancer	0.00191	0.00211	CcSEcCtD
Triamcinolone—Ecchymosis—Methotrexate—lymphatic system cancer	0.0019	0.0021	CcSEcCtD
Triamcinolone—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00189	0.00209	CcSEcCtD
Triamcinolone—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.00187	0.00207	CcSEcCtD
Triamcinolone—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00186	0.00206	CcSEcCtD
Triamcinolone—Oedema—Bleomycin—lymphatic system cancer	0.00185	0.00205	CcSEcCtD
Triamcinolone—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00185	0.00205	CcSEcCtD
Triamcinolone—Erythema—Mitoxantrone—lymphatic system cancer	0.00184	0.00204	CcSEcCtD
Triamcinolone—Infection—Bleomycin—lymphatic system cancer	0.00184	0.00204	CcSEcCtD
Triamcinolone—Back pain—Vincristine—lymphatic system cancer	0.00183	0.00203	CcSEcCtD
Triamcinolone—Vomiting—Teniposide—lymphatic system cancer	0.00183	0.00202	CcSEcCtD
Triamcinolone—Asthenia—Fludarabine—lymphatic system cancer	0.00181	0.00201	CcSEcCtD
Triamcinolone—Rash—Teniposide—lymphatic system cancer	0.00181	0.00201	CcSEcCtD
Triamcinolone—Dermatitis—Teniposide—lymphatic system cancer	0.00181	0.00201	CcSEcCtD
Triamcinolone—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.0018	0.002	CcSEcCtD
Triamcinolone—Headache—Teniposide—lymphatic system cancer	0.0018	0.00199	CcSEcCtD
Triamcinolone—Pruritus—Fludarabine—lymphatic system cancer	0.00179	0.00198	CcSEcCtD
Triamcinolone—Back pain—Mitoxantrone—lymphatic system cancer	0.00178	0.00197	CcSEcCtD
Triamcinolone—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.00176	0.00195	CcSEcCtD
Triamcinolone—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.00175	0.00194	CcSEcCtD
Triamcinolone—Convulsion—Carmustine—lymphatic system cancer	0.00172	0.0019	CcSEcCtD
Triamcinolone—Hypertension—Carmustine—lymphatic system cancer	0.00171	0.00189	CcSEcCtD
Triamcinolone—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00171	0.00189	CcSEcCtD
Triamcinolone—Nausea—Teniposide—lymphatic system cancer	0.00171	0.00189	CcSEcCtD
Triamcinolone—Vertigo—Vincristine—lymphatic system cancer	0.0017	0.00188	CcSEcCtD
Triamcinolone—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00169	0.00187	CcSEcCtD
Triamcinolone—Myalgia—Carmustine—lymphatic system cancer	0.00169	0.00187	CcSEcCtD
Triamcinolone—Paraesthesia—Bleomycin—lymphatic system cancer	0.00166	0.00184	CcSEcCtD
Triamcinolone—Malaise—Mitoxantrone—lymphatic system cancer	0.00166	0.00184	CcSEcCtD
Triamcinolone—Dyspnoea—Bleomycin—lymphatic system cancer	0.00165	0.00183	CcSEcCtD
Triamcinolone—Convulsion—Vincristine—lymphatic system cancer	0.00164	0.00181	CcSEcCtD
Triamcinolone—Hypertension—Vincristine—lymphatic system cancer	0.00163	0.00181	CcSEcCtD
Triamcinolone—Oedema—Carmustine—lymphatic system cancer	0.00162	0.00179	CcSEcCtD
Triamcinolone—Myalgia—Vincristine—lymphatic system cancer	0.00161	0.00178	CcSEcCtD
Triamcinolone—Cough—Mitoxantrone—lymphatic system cancer	0.00161	0.00178	CcSEcCtD
Triamcinolone—Infection—Carmustine—lymphatic system cancer	0.00161	0.00178	CcSEcCtD
Triamcinolone—Vomiting—Fludarabine—lymphatic system cancer	0.00161	0.00178	CcSEcCtD
Triamcinolone—Convulsion—Mitoxantrone—lymphatic system cancer	0.0016	0.00177	CcSEcCtD
Triamcinolone—Rash—Fludarabine—lymphatic system cancer	0.00159	0.00176	CcSEcCtD
Triamcinolone—Dermatitis—Fludarabine—lymphatic system cancer	0.00159	0.00176	CcSEcCtD
Triamcinolone—Hypertension—Mitoxantrone—lymphatic system cancer	0.00159	0.00176	CcSEcCtD
Triamcinolone—Pain—Bleomycin—lymphatic system cancer	0.00158	0.00175	CcSEcCtD
Triamcinolone—Headache—Fludarabine—lymphatic system cancer	0.00158	0.00175	CcSEcCtD
Triamcinolone—Tachycardia—Carmustine—lymphatic system cancer	0.00158	0.00175	CcSEcCtD
Triamcinolone—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00157	0.00174	CcSEcCtD
Triamcinolone—Myalgia—Mitoxantrone—lymphatic system cancer	0.00157	0.00174	CcSEcCtD
Triamcinolone—Discomfort—Mitoxantrone—lymphatic system cancer	0.00155	0.00172	CcSEcCtD
Triamcinolone—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00154	0.00171	CcSEcCtD
Triamcinolone—Oedema—Vincristine—lymphatic system cancer	0.00154	0.00171	CcSEcCtD
Triamcinolone—Infection—Vincristine—lymphatic system cancer	0.00153	0.0017	CcSEcCtD
Triamcinolone—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00153	0.00169	CcSEcCtD
Triamcinolone—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00152	0.00169	CcSEcCtD
Triamcinolone—Oedema—Mitoxantrone—lymphatic system cancer	0.0015	0.00166	CcSEcCtD
Triamcinolone—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.0015	0.00166	CcSEcCtD
Triamcinolone—Nausea—Fludarabine—lymphatic system cancer	0.0015	0.00166	CcSEcCtD
Triamcinolone—Infection—Mitoxantrone—lymphatic system cancer	0.00149	0.00165	CcSEcCtD
Triamcinolone—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00149	0.00165	CcSEcCtD
Triamcinolone—Shock—Mitoxantrone—lymphatic system cancer	0.00148	0.00164	CcSEcCtD
Triamcinolone—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00147	0.00163	CcSEcCtD
Triamcinolone—Urticaria—Bleomycin—lymphatic system cancer	0.00147	0.00163	CcSEcCtD
Triamcinolone—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00147	0.00162	CcSEcCtD
Triamcinolone—Body temperature increased—Bleomycin—lymphatic system cancer	0.00146	0.00162	CcSEcCtD
Triamcinolone—Insomnia—Carmustine—lymphatic system cancer	0.00146	0.00162	CcSEcCtD
Triamcinolone—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00145	0.00161	CcSEcCtD
Triamcinolone—Paraesthesia—Carmustine—lymphatic system cancer	0.00145	0.00161	CcSEcCtD
Triamcinolone—Mood swings—Methotrexate—lymphatic system cancer	0.00144	0.0016	CcSEcCtD
Triamcinolone—Dyspnoea—Carmustine—lymphatic system cancer	0.00144	0.0016	CcSEcCtD
Triamcinolone—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00141	0.00156	CcSEcCtD
Triamcinolone—Insomnia—Vincristine—lymphatic system cancer	0.0014	0.00155	CcSEcCtD
Triamcinolone—Paraesthesia—Vincristine—lymphatic system cancer	0.00139	0.00153	CcSEcCtD
Triamcinolone—Pain—Carmustine—lymphatic system cancer	0.00138	0.00153	CcSEcCtD
Triamcinolone—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00137	0.00152	CcSEcCtD
Triamcinolone—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00137	0.00151	CcSEcCtD
Triamcinolone—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00135	0.00149	CcSEcCtD
Triamcinolone—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00134	0.00148	CcSEcCtD
Triamcinolone—Feeling abnormal—Carmustine—lymphatic system cancer	0.00133	0.00148	CcSEcCtD
Triamcinolone—Fatigue—Vincristine—lymphatic system cancer	0.00133	0.00147	CcSEcCtD
Triamcinolone—Asthenia—Bleomycin—lymphatic system cancer	0.00133	0.00147	CcSEcCtD
Triamcinolone—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00132	0.00147	CcSEcCtD
Triamcinolone—Pain—Vincristine—lymphatic system cancer	0.00132	0.00146	CcSEcCtD
Triamcinolone—Asthma—Methotrexate—lymphatic system cancer	0.00132	0.00146	CcSEcCtD
Triamcinolone—Pruritus—Bleomycin—lymphatic system cancer	0.00131	0.00145	CcSEcCtD
Triamcinolone—Fatigue—Mitoxantrone—lymphatic system cancer	0.0013	0.00144	CcSEcCtD
Triamcinolone—Pancreatitis—Methotrexate—lymphatic system cancer	0.00129	0.00143	CcSEcCtD
Triamcinolone—Pain—Mitoxantrone—lymphatic system cancer	0.00129	0.00142	CcSEcCtD
Triamcinolone—Body temperature increased—Carmustine—lymphatic system cancer	0.00128	0.00142	CcSEcCtD
Triamcinolone—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00124	0.00137	CcSEcCtD
Triamcinolone—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00122	0.00136	CcSEcCtD
Triamcinolone—Body temperature increased—Vincristine—lymphatic system cancer	0.00122	0.00135	CcSEcCtD
Triamcinolone—Urticaria—Mitoxantrone—lymphatic system cancer	0.00119	0.00132	CcSEcCtD
Triamcinolone—Hypersensitivity—Carmustine—lymphatic system cancer	0.00119	0.00132	CcSEcCtD
Triamcinolone—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00119	0.00132	CcSEcCtD
Triamcinolone—Vomiting—Bleomycin—lymphatic system cancer	0.00118	0.0013	CcSEcCtD
Triamcinolone—Rash—Bleomycin—lymphatic system cancer	0.00117	0.00129	CcSEcCtD
Triamcinolone—Dermatitis—Bleomycin—lymphatic system cancer	0.00117	0.00129	CcSEcCtD
Triamcinolone—Asthenia—Carmustine—lymphatic system cancer	0.00116	0.00128	CcSEcCtD
Triamcinolone—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00114	0.00126	CcSEcCtD
Triamcinolone—Hypersensitivity—Vincristine—lymphatic system cancer	0.00114	0.00126	CcSEcCtD
Triamcinolone—Epistaxis—Methotrexate—lymphatic system cancer	0.00111	0.00123	CcSEcCtD
Triamcinolone—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00111	0.00123	CcSEcCtD
Triamcinolone—Asthenia—Vincristine—lymphatic system cancer	0.00111	0.00123	CcSEcCtD
Triamcinolone—Nausea—Bleomycin—lymphatic system cancer	0.0011	0.00122	CcSEcCtD
Triamcinolone—Asthenia—Mitoxantrone—lymphatic system cancer	0.00108	0.00119	CcSEcCtD
Triamcinolone—Dizziness—Carmustine—lymphatic system cancer	0.00107	0.00118	CcSEcCtD
Triamcinolone—Haemoglobin—Methotrexate—lymphatic system cancer	0.00106	0.00117	CcSEcCtD
Triamcinolone—Haemorrhage—Methotrexate—lymphatic system cancer	0.00105	0.00117	CcSEcCtD
Triamcinolone—Pharyngitis—Methotrexate—lymphatic system cancer	0.00105	0.00116	CcSEcCtD
Triamcinolone—Vomiting—Carmustine—lymphatic system cancer	0.00103	0.00114	CcSEcCtD
Triamcinolone—Dizziness—Vincristine—lymphatic system cancer	0.00102	0.00113	CcSEcCtD
Triamcinolone—Rash—Carmustine—lymphatic system cancer	0.00102	0.00113	CcSEcCtD
Triamcinolone—Dermatitis—Carmustine—lymphatic system cancer	0.00102	0.00113	CcSEcCtD
Triamcinolone—Headache—Carmustine—lymphatic system cancer	0.00101	0.00112	CcSEcCtD
Triamcinolone—Vomiting—Vincristine—lymphatic system cancer	0.000982	0.00109	CcSEcCtD
Triamcinolone—Rash—Vincristine—lymphatic system cancer	0.000973	0.00108	CcSEcCtD
Triamcinolone—Dermatitis—Vincristine—lymphatic system cancer	0.000973	0.00108	CcSEcCtD
Triamcinolone—Headache—Vincristine—lymphatic system cancer	0.000967	0.00107	CcSEcCtD
Triamcinolone—Nausea—Carmustine—lymphatic system cancer	0.000961	0.00106	CcSEcCtD
Triamcinolone—Vomiting—Mitoxantrone—lymphatic system cancer	0.000956	0.00106	CcSEcCtD
Triamcinolone—Rash—Mitoxantrone—lymphatic system cancer	0.000948	0.00105	CcSEcCtD
Triamcinolone—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000947	0.00105	CcSEcCtD
Triamcinolone—Headache—Mitoxantrone—lymphatic system cancer	0.000942	0.00104	CcSEcCtD
Triamcinolone—Erythema—Methotrexate—lymphatic system cancer	0.000918	0.00102	CcSEcCtD
Triamcinolone—Nausea—Vincristine—lymphatic system cancer	0.000917	0.00102	CcSEcCtD
Triamcinolone—Dysgeusia—Methotrexate—lymphatic system cancer	0.000899	0.000995	CcSEcCtD
Triamcinolone—Nausea—Mitoxantrone—lymphatic system cancer	0.000893	0.000989	CcSEcCtD
Triamcinolone—Back pain—Methotrexate—lymphatic system cancer	0.000888	0.000983	CcSEcCtD
Triamcinolone—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000852	0.000943	CcSEcCtD
Triamcinolone—Malaise—Methotrexate—lymphatic system cancer	0.000828	0.000916	CcSEcCtD
Triamcinolone—Vertigo—Methotrexate—lymphatic system cancer	0.000825	0.000913	CcSEcCtD
Triamcinolone—Cough—Methotrexate—lymphatic system cancer	0.000801	0.000887	CcSEcCtD
Triamcinolone—Convulsion—Methotrexate—lymphatic system cancer	0.000795	0.00088	CcSEcCtD
Triamcinolone—Myalgia—Methotrexate—lymphatic system cancer	0.000781	0.000865	CcSEcCtD
Triamcinolone—Discomfort—Methotrexate—lymphatic system cancer	0.000772	0.000855	CcSEcCtD
Triamcinolone—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000749	0.000829	CcSEcCtD
Triamcinolone—Infection—Methotrexate—lymphatic system cancer	0.000744	0.000824	CcSEcCtD
Triamcinolone—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000724	0.000802	CcSEcCtD
Triamcinolone—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000682	0.000756	CcSEcCtD
Triamcinolone—Insomnia—Methotrexate—lymphatic system cancer	0.000678	0.00075	CcSEcCtD
Triamcinolone—Paraesthesia—Methotrexate—lymphatic system cancer	0.000673	0.000745	CcSEcCtD
Triamcinolone—Dyspnoea—Methotrexate—lymphatic system cancer	0.000668	0.000739	CcSEcCtD
Triamcinolone—Dyspepsia—Methotrexate—lymphatic system cancer	0.000659	0.00073	CcSEcCtD
Triamcinolone—Fatigue—Methotrexate—lymphatic system cancer	0.000646	0.000715	CcSEcCtD
Triamcinolone—Pain—Methotrexate—lymphatic system cancer	0.000641	0.000709	CcSEcCtD
Triamcinolone—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000617	0.000683	CcSEcCtD
Triamcinolone—Urticaria—Methotrexate—lymphatic system cancer	0.000595	0.000659	CcSEcCtD
Triamcinolone—Body temperature increased—Methotrexate—lymphatic system cancer	0.000592	0.000656	CcSEcCtD
Triamcinolone—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000552	0.000611	CcSEcCtD
Triamcinolone—Asthenia—Methotrexate—lymphatic system cancer	0.000537	0.000595	CcSEcCtD
Triamcinolone—Pruritus—Methotrexate—lymphatic system cancer	0.00053	0.000587	CcSEcCtD
Triamcinolone—Dizziness—Methotrexate—lymphatic system cancer	0.000495	0.000548	CcSEcCtD
Triamcinolone—Vomiting—Methotrexate—lymphatic system cancer	0.000476	0.000527	CcSEcCtD
Triamcinolone—Rash—Methotrexate—lymphatic system cancer	0.000472	0.000523	CcSEcCtD
Triamcinolone—Dermatitis—Methotrexate—lymphatic system cancer	0.000472	0.000522	CcSEcCtD
Triamcinolone—Headache—Methotrexate—lymphatic system cancer	0.000469	0.00052	CcSEcCtD
Triamcinolone—Nausea—Methotrexate—lymphatic system cancer	0.000445	0.000493	CcSEcCtD
